Mark & Associates, P.C. Attorneys At Law

Heart Medication Digitek Recalled Amid Double-Dose Concerns

A nationwide recall has been ordered for the heart-failure medication Digitek (digoxin) after an unknown number of pills thought to contain twice the dose of the drug's active ingredient were given to patients.

About a dozen reports of deaths, illness, and injuries to patients taking the drug have been reported since the suspected double-doses were discovered. The recall was ordered in April 2008, but it is unknown how many double-dose pills were distributed to patients.

Digitek is commonly used to treat heart failure and abnormal heart rhythm in both humans and animals. An overdose of the drug can result in vomiting, nausea, cardiac instability, low blood pressure, dizziness, and even death. The double dosages also pose an increased risk of digoxin toxicity in patients with renal failure.

Digitek is manufactured by Actavis Totowa LLC, a United States division of the international generic pharmaceutical company Actavis Group. The drug is distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label.

The pills thought to contain twice the active ingredient are approximately twice the size of doses containing the proper amount of active ingredient, officials said. However, the size of the pills is not a reliable way to determine whether the pills contain a dangerous double dose.

Patients with prescriptions for Digitek should stop taking the mediation immediately and return the unused does to their pharmacy or treating physician.

Legal Advice is Available for Digitek Patients

Mark & Associates, P.C. is aggressively representing individuals who have died or suffered injuries after taking double-dose Digitek tablets. Our law firm is available 24/7 to answer any questions you may have. Contact us today for a free, no obligation, legal consultation by completing the case evaluation form on the right side of this page or by calling 1-866-50-RIGHTS (1-866-507-4448).